title: The role of ets factors in tumor angiogenesis.
abstract: Angiogenesis is a critical component of tumor growth. A number of growth factors, including VEGF, FGF, and HGF, have been implicated as angiogenic growth factors that promote tumor angiogenesis in different types of cancer. Ets-1 is the prototypic member of the Ets transcription factor family. Ets-1 is known to be a downstream mediator of angiogenic growth factors. Expression of Ets-1 in a variety of different tumors is associated with increased angiogenesis. A role for other selected members of the Ets transcription factor family has also been shown to be important for the development of tumor angiogenesis. Because Ets factors also express a number of other important genes involved in cell growth, they contribute not only to tumor growth, but to disease progression. Targeting Ets factors in mouse tumor models through the use of dominant-negative Ets proteins or membrane permeable peptides directed at competitively inhibiting the DNA binding domain has now demonstrated the therapeutic potential of inhibiting selected Ets transcription factors to limit tumor growth and disease progression.
authors.affiliation: Division of Cardiology, and Molecular and Vascular Biology, Department of Medicine, Research North RM 270D, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Oettgen
references.citation: Blood. 2009 Jul 30;114(5):934-5
references.pmid: 19643995
references.citation: J Biol Chem. 1995 Oct 13;270(41):24258-63
references.pmid: 7592633
references.citation: Oncogene. 2008 Jun 12;27(26):3662-72
references.pmid: 18212735
references.citation: J Virol. 2007 Apr;81(8):3980-91
references.pmid: 17287278
references.citation: Genes Dev. 1998 May 1;12(9):1315-26
references.pmid: 9573048
references.citation: Blood. 2009 Jul 30;114(5):1123-30
references.pmid: 19411629
references.citation: Mol Cell Biol. 2003 Dec;23(23):8614-25
references.pmid: 14612405
references.citation: J Cancer Res Clin Oncol. 2003 Jul;129(7):430-6
references.pmid: 12851814
references.citation: J Clin Invest. 2005 Sep;115(9):2508-16
references.pmid: 16138193
references.citation: Verh Dtsch Ges Pathol. 1999;83:212-5
references.pmid: 10714212
references.citation: Cancer Sci. 2003 Sep;94(9):769-73
references.pmid: 12967474
references.citation: Oncogene. 2002 Dec 5;21(55):8506-9
references.pmid: 12466970
references.citation: Hum Pathol. 2009 Apr;40(4):588-93
references.pmid: 18992913
references.citation: Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9184-9
references.pmid: 9689055
references.citation: Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1803-9
references.pmid: 15284088
references.citation: Blood. 1998 Feb 15;91(4):1399-406
references.pmid: 9454771
references.citation: Cancer Lett. 2000 Nov 10;160(1):45-50
references.pmid: 11098083
references.citation: J Biomed Sci. 2003 May-Jun;10(3):320-7
references.pmid: 12711859
references.citation: Circulation. 2004 Jun 22;109(24):3035-41
references.pmid: 15173033
references.citation: Ann Oncol. 2002 Oct;13(10):1605-11
references.pmid: 12377649
references.citation: Lab Invest. 1999 Apr;79(4):407-16
references.pmid: 10211993
references.citation: Biochem Biophys Res Commun. 2001 Nov 23;289(1):39-43
references.pmid: 11708773
references.citation: Mod Pathol. 1999 Jun;12(6):618-26
references.pmid: 10392639
references.citation: Circ Res. 1999 May 28;84(10):1177-85
references.pmid: 10347092
references.citation: Nucleic Acids Res. 2003 Dec 1;31(23):e152
references.pmid: 14627842
references.citation: Nature. 2009 Oct 22;461(7267):1084-91
references.pmid: 19847259
references.citation: Int Surg. 2003 Jan-Mar;88(1):25-33
references.pmid: 12731728
references.citation: Zhonghua Bing Li Xue Za Zhi. 2002 Jun;31(3):222-6
references.pmid: 12475439
references.citation: Immunity. 1998 Oct;9(4):555-63
references.pmid: 9806641
references.citation: Eur J Biochem. 1993 Jan 15;211(1-2):7-18
references.pmid: 8425553
references.citation: J Biol Chem. 2006 Sep 1;281(35):25259-69
references.pmid: 16829517
references.citation: Cancer Gene Ther. 2009 Feb;16(2):137-48
references.pmid: 18772901
references.citation: FASEB J. 1999 Feb;13(2):377-86
references.pmid: 9973326
references.citation: J Biol Chem. 2003 Dec 5;278(49):49358-68
references.pmid: 14507917
references.citation: Ann Oncol. 2002 Oct;13(10):1598-604
references.pmid: 12377648
references.citation: Cancer Res. 1997 May 15;57(10):2013-9
references.pmid: 9157999
references.citation: Br J Haematol. 2008 Dec;143(5):622-31
references.pmid: 19036013
references.citation: Cancer Res. 2008 Jun 15;68(12):4649-57
references.pmid: 18559510
references.citation: Oncology. 2004;66(5):420-8
references.pmid: 15331930
references.citation: Oncogene. 2003 Mar 27;22(12):1795-806
references.pmid: 12660815
references.citation: J Biol Chem. 2003 Feb 28;278(9):7520-30
references.pmid: 12464608
references.citation: J Immunol. 2006 Aug 15;177(4):2651-61
references.pmid: 16888027
references.citation: Neoplasia. 2007 Mar;9(3):184-91
references.pmid: 17401458
references.citation: Blood. 2006 Apr 15;107(8):3153-60
references.pmid: 16352813
references.citation: Mol Cell. 2001 Dec;8(6):1267-76
references.pmid: 11779502
references.citation: Mech Dev. 2000 Feb;90(2):237-52
references.pmid: 10640707
references.citation: Oncogene. 2006 Nov 2;25(52):6959-67
references.pmid: 16715134
references.citation: Circ Res. 2001 Feb 2;88(2):237-44
references.pmid: 11157678
references.citation: Curr Drug Targets. 2007 Feb;8(2):257-68
references.pmid: 17305503
references.citation: J Immunol. 1998 Dec 1;161(11):6084-92
references.pmid: 9834092